Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes

61Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE - Insulin and glucose levels in response to premeal insulin lispro or repaglinide were evaluated in adult patients with cystic fibrosis-related diabetes (CFRD) without fasting hyperglycemia. RESEARCH DESIGN AND METHODS - Seven patients with CFRD were fed 1,000-kcal liquid mixed meals. Three study conditions were administered in random order on separate mornings: 1) no premeal diabetes medication, 2) insulin lispro, 0.1 unit/kg body wt premeal and 3) repaglinide 1 mg premeal. Glucose and insulin levels were measured every 20 min for 5 h. RESULTS - Fasting insulin and glucose levels were normal in patients with CFRD, but the peak glucose level was elevated. Insulin lispro significantly decreased the peak glucose level (P = 0.0004) and the 2-h (P = 0.001) and 5-h (P < 0.0001) glucose area under the curve (AUC). Repaglinide significantly decreased the 5-h glucose AUC (P = 0.03). Neither drug completely normalized cystic fibrosis glucose excursion at the doses used for this study. Insulin lispro significantly increased the 5-h insulin AUC (P = 0.04). CONCLUSIONS -In response to subcutaneous insulin lispro, postprandial glucose excursion was significantly diminished and insulin secretion was enhanced compared with a control meal in which no medication was given to patients with CFRD. The oral agent repaglinide resulted in lesser corrections in these parameters. Neither drug completely normalized glucose or insulin levels, suggesting that the doses chosen for this study were suboptimal. Placebo-controlled longitudinal studies comparing the effectiveness of repaglinide and insulin on glucose metabolic control as well as overall nutrition and body weight are needed to help determine optimal medical treatment of CFRD.

References Powered by Scopus

[Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin

544Citations
N/AReaders
Get full text

Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline

316Citations
N/AReaders
Get full text

Diabetes mellitus associated with cystic fibrosis

273Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society

564Citations
N/AReaders
Get full text

Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: Results of the cystic fibrosis related diabetes therapy trial

199Citations
N/AReaders
Get full text

Clinical importance of cystic fibrosis-related diabetes

124Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Moran, A., Phillips, J., & Milla, C. (2001). Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care, 24(10), 1706–1710. https://doi.org/10.2337/diacare.24.10.1706

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

50%

Researcher 5

28%

Professor / Associate Prof. 2

11%

Lecturer / Post doc 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

58%

Biochemistry, Genetics and Molecular Bi... 4

17%

Pharmacology, Toxicology and Pharmaceut... 3

13%

Nursing and Health Professions 3

13%

Save time finding and organizing research with Mendeley

Sign up for free